Search
Charles River Laboratories International Inc
CRLAdd to Watchlist
292.840USD
-1.600-0.54%
Close 09-25 16:00（ET）
14.11BMarket Cap
LossP/E TTM
After-hours 19:00 (ET)292.840USD+0.420+0.14%
After-hours 19:00 (ET)Charles River Laboratories International Inc (CRL) Stock Price Target & Forecast
Analyst Rating
Based on 19 analysts giving stock ratings to Charles River Laboratories International Inc in the past month.
Buy
5 Strong Buy
9 Buy
5 Hold
0 Sell
0 Strong Sell
Target Price
293.321USD-0.38%
CRL Analyst Recommendation Trends
In the current month, CRL has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the last month is 293.321.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
5
6
6
6
6
6
9
9
8
7
6
5
5
5
5
5
6
7
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
19
19
20
20
19
19
19
CRL Analyst Rating for Peer Comparison
Updated: Sep 25, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, CRL EPS is projected to reach 2.956 in FY2026Q3, following reported EPS of -0.031 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
2.34
1.94
2.74
2.96
3.32
Actual
-5.62
-0.30
-0.03
--
--
Surprise
-339.79%
-115.61%
-101.13%
--
--
FAQs
What is Charles River Laboratories International Inc's expected revenue for the next quarter?
Charles River Laboratories International Inc's expected revenue is 957.71M.
What is Charles River Laboratories International Inc's price target?
Analysts forecast that Charles River Laboratories International Inc's price target is USD 280.72, with the highest forecast at USD 330.00 and the lowest forecast at USD 145.81.
How have Charles River Laboratories International IncCRL's recent earnings per share performed?
The market expectation was USD -0.03, while Charles River Laboratories International IncCRL's earnings per share (EPS) for the previous quarter was USD -0.30. EPS for the next quarter is expected at USD 2.95.
What is the analyst rating for Charles River Laboratories International Inc?
Based on the ratings of Charles River Laboratories International Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.